

NATIONAL ANTIBIOTIC GUIDELINES 2017



National Antibiotic Guidelines 2017:

What Pediatricians Should Know

Carmina A. delos Reyes, M.D.



Objectives

Discuss the National Antibiotic Guidelines

- What is it?
- Why is it needed?
- How is it used?

Guide pediatricians on how to use antibiotics judiciously



Outline

National Antibiotic Guidelines 2017:

- What? Why? How?

Use of the National Antibiotic Guidelines in Common Clinical Scenarios



What is the National Antibiotic Guidelines?

Is a set of treatment recommendations for infectious diseases across organ systems

Consists of brief descriptions of disease categories with etiologic agents and corresponding antibiotic regimens



Why is it needed?

Is integral to combat antimicrobial resistance

Is a core element of antimicrobial stewardship

- intended to improve antimicrobial prescribing and dispensing
- intended to optimize antimicrobial use and help improve quality of patient care



How did the guidelines come about?

Creation of the National Antibiotic
Guidelines Committee in 2014



NAGCOM Composition

Chair: Dr. Mediadora C. Saniel (Dr. Estrella Paje-Villar)

Members:

Dr. M. Delos Reyes - Philippine Society for Microbiology and Infectious Diseases

Dr. B. Galvez - Philippine Hospital Infection Control Society

Dr. C. delos Reyes - *Pediatric Infectious Disease Society of the Philippines*

Dr. O. Limuaco - Philippine Pharmacists Association

Dr. C. Lazarte - Formulary Executive Council

Dr. C. Carlos - Research Institute for Tropical Medicine

Dr. R. Vianzon - National Center for Disease Prevention and Control

Dr. M. Lansang - UP College of Medicine

Dr. V. Roque - National Epidemiology Center

Dr. C. Fabregas - National Center for Health Facilities and Development

Secretariat: Pharmaceutical Division of the Department of Health



How did the guidelines come about?

Review of evidence-based local and international guidelines and literature, with priority given to those that utilized the **GRADE system**

(Grading of *R*ecommendations *A*ssessment, *D*evelopment and *E*valuation)



How did the guidelines come about?

Adaptation of available guidelines and treatment recommendations were made with the following considerations:

- ARSP rates
- Approved drugs in the National Formulary
- Quality of evidence
- Balance of potential benefits and harm
- Cost-effectiveness
- Availability of diagnostic tests
- Feasibility and resource implications



How did the guidelines come about?

Interim recommendations were discussed *en banc* and a consensus reached

Guidelines were sent to specialty/subspecialty societies for inputs prior to release

Consultation with external technical experts and public health program implementers were done



Government Agencies, Academia and Professional Medical Societies as Resource Persons/Technical Experts

Philippine Dental Association

Philippine Dermatological Society

Philippine Academy of Pediatric Pulmonologists

Philippine College of Chest Physicians

Philippine College of Physicians

Philippine College of Surgeons

Philippine Pediatric Society

Philippine Obstetrical and Gynecological Society

Philippine Society of Otolaryngology Head and Neck Surgery

Philippine Academy of Ophthalmology

Philippine Academy of Family Physicians

Philippine Neurological Association

Philippine Society of Nephrology



How is it used?

<http://icamr.doh.gov.ph>

Antimicrobial Stewardship Toolkit


Antimicrobial Stewardship Program in Hospitals MOP
National Antibiotic Guidelines





ICAMR

Interagency Committee on Antimicrobial Resistance

YOU ARE HERE: [HOME](#) / [NATIONAL ANTIBIOTIC GUIDELINES](#)

Antimicrobial Stewardship Toolkit

[Antimicrobial Stewardship Program in Hospitals Manual of Procedures](#)

[National Antibiotic Guidelines](#)

EVENTS

- [AMR Summit](#)
- [AMS Workshop](#)
- [AMU Workshop](#)

**TABLE OF CONTENTS**

[MESSAGE OF THE SECRETARY OF HEALTH](#)

[ACKNOWLEDGEMENTS](#)

[EDITORIAL TEAM](#)

[ABBREVIATIONS AND ACRONYMS](#)

[INTRODUCTION](#)

[NATIONAL ANTIBIOTIC GUIDELINES \(FULL VERSION\)](#)

[BLOOD BORNE INFECTIONS \(as of November 2017\)](#)

[BONE AND JOINT INFECTIONS IN PEDIATRICS \(as of November 2017\)](#)

[BONE AND JOINT INFECTIONS IN ADULTS \(as of November 2017\)](#)

[CARDIOVASCULAR INFECTIONS \(as of November 2017\)](#)

[CENTRAL NERVOUS SYSTEM INFECTIONS \(as of November 2017\)](#)

[DENTAL AND ORAL INFECTIONS \(as of November 2017\)](#)

[GASTROINTESTINAL TRACT INFECTIONS \(as of November 2017\)](#)

[OCULAR INFECTIONS \(as of November 2017\)](#)

[UPPER RESPIRATORY INFECTIONS \(as of November 2017\)](#)

[LOWER RESPIRATORY INFECTIONS \(as of November 2017\)](#)

[SKIN AND SOFT TISSUE INFECTIONS IN ADULTS \(as of November 2017\)](#)

[SKIN AND SOFT TISSUE INFECTIONS IN PEDIATRICS \(as of November 2017\)](#)

[URINARY TRACT INFECTIONS \(as of November 2017\)](#)

NAGCom Guidelines

Public Health Programmes

Filariasis

Leprosy

Malaria

Schistosomiasis

Sexually Transmitted Infections

Tuberculosis



NAGCom Guidelines

Organ System Specific Infections

Blood

Bone and Joint

Cardiovascular

Central Nervous System

Dental and Oral



NAGCom Guidelines

Organ System Specific Infections

Gastrointestinal Tract

Ocular

Respiratory Tract

Skin and Soft Tissue

Urinary Tract Infection



Top Causes Child Mortality/Morbidity

1. Pneumonia
2. Diarrhea
3. Sepsis
4. Meningitis
5. UTI



Use of the National Antibiotic Guidelines in Common Clinical Scenarios





Case 1: Rosalinda

6 years, female

sudden onset of fever, sore throat, no cough

Associated symptoms: headache, vomiting

Relevant exposure: none

PE: hyperemic pharynx, enlarged tonsils with exudates, (+) palatal petechiae, enlarged and tender anterior cervical lymph nodes



Case 1: Rosalinda



Case 1: Rosalinda

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 1: Rosalinda

- A. Diphtheria
- B. Infectious Mononucleosis
- C. Exudative Pharyngitis



EXUDATIVE PHARYNGITIS

Etiology	Preferred Regimen	Comments
<p>Group A, C, G Streptococci</p> <p>Fusobacterium</p>	<p>Penicillin V 50 mg/kg/day PO q6h x 10 days OR</p> <p>Amoxicillin 50 mg/kg/day PO q 8-12h x 10 days (Max: 1g/day)</p> <p><u>Penicillin Allergy:</u> Erythromycin OR Clarithromycin OR Azithromycin may be given</p>	<p>cough, rhinorrhea, hoarseness, oral ulcers suggest a viral etiology</p> <p>Cotrimoxazole, Tetracyclines, FQs not effective; Co-amoxiclav NOT recommended</p> <p>Resistance to macrolides have been reported</p>

Case 1: Rosalinda

Is an antibiotic necessary?



URTI Guidelines

Acute epiglottitis

Diphtheria

Gonococcal pharyngitis

Laryngitis

Lemierre's syndrome

Mastoiditis

Otitis Media

Peritonsillar abscess

Recurrent pharyngitis

Retropharyngeal abscess

Sinusitis

Viral pharyngitis





Case 2: Estrella

5 months, female

colds x 5 days

cough, wheezing, fever x 3 days

Relevant exposures: colds in both parents

PE: RR-55, T-38.4°C; rhinorrhea; intercostal and subcostal retractions, diffuse fine inspiratory crackles & expiratory wheezes



Case 2: Estrella

CBC:

normal WBC count,
differential ct.-mononuclear predominance

CXR:

hyperaerated lungs,
peribronchial thickening, no infiltrates



Case 2: Estrella



Case 2: Estrella

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 2: Estrella

- A. Bronchiolitis
- B. Pertussis
- C. Pneumonia



BRONCHIOLITIS

Etiology	Preferred Regimen	Comments
<p>RSV 50% HPIV 25% Human Metapneumo- virus</p>	<p><u>< 5 y:</u> Ribavirin for severe disease (requiring MV).</p>	<p>ANTIBIOTICS ARE NOT INDICATED unless there is secondary bacterial infection.</p> <p>The mainstay of therapy is supportive care.</p>

Case 2 : Estrella

Is an antibiotic necessary?





Case 3: Lulu

6 years, female

colds x 2 days followed by productive cough 4 days later

Associated symptom: occasional vomiting
cough has been there for over a week
and now with sputum purulence

PE: T-38 °C, crackles and scattered wheezes



Case 3: Lulu

CBC: not available

CXR: normal



Case 3: Lulu

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 3: Lulu

- A. Bronchiolitis
- B. Bronchitis
- C. Bronchiectasis



BRONCHITIS

Etiology	Preferred Regimen	Comments
<p><2 y: Adenovirus</p> <p>>2-5 y: RSV PIV Human metapneumovirus</p>	<p>No antibiotics, unless there is sinusitis or if with heavy growth on throat culture for: <i>S. pneumoniae,</i> <i>GAS, H. influenzae</i></p>	<p>Purulent sputum alone is NOT an indication to start antibiotics.</p> <p>Expect the illness to last for about 2 weeks.</p>

Case 3: Lulu

Is an antibiotic necessary?





Case 4 : Josie

4 years, female

colds and cough x 4 days, with high fever today with slight decrease in appetite

Relevant exposure: no illness within family

Immunization history: unknown

PE: RR-32, asleep, eyes not sunken, no nasal flaring, no subcostal and intercostal retractions, (+) scattered crackles and rhonchi



Case 4: Josie

CBC: WBC 15,000; ↑segmenter


CXR: confluent infiltrates, LLL



Case 4: Josie

L

A/105/2.4/10.2/517



Case 4 : Josie

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 4: Josie

- A. Bronchitis
- B. Bronchiectasis
- C. Pneumonia



CAP in CHILDREN UP TO 5 YEARS

Pediatric CAP (PCAP) Classification:

PCAP A/B (non-severe):

No or mild dehydration

no malnutrition

no pallor

awake

no signs of respiratory failure

respiratory rate of ≥ 50 - ≥ 60 /min (3-12 mos.),

≥ 40 - ≤ 50 /min (1-5y), ≥ 30 - ≤ 35 /min (>5 years)



CAP in CHILDREN UP TO 5 YEARS

Pediatric CAP (PCAP) Classification:

PCAP C (severe):

Moderate dehydration
moderate malnutrition
with pallor

irritable (+) intercostal/ subcostal retractions, head bobbing, cyanosis)

respiratory rate of >60 - ≤ 70 /min (3-12 mos),

>50 /min (1-5 y), >35 /min (>5 y)

NO grunting; NO apnea



CAP in CHILDREN UP TO 5 YEARS

Pediatric CAP (PCAP) Classification:

PCAP D (very severe):

Severe dehydration
severe malnutrition
with pallor

lethargic/ stuporous/in coma

(+)supraclavicular/intercostal/subcostal retractions,
head bobbing, cyanosis, grunting, apnea

respiratory rate >70/min (3-12 mos), >50/min (1-5 y),
>35/min (>5 y)



ARSP 2016

S. pneumoniae: **Cumulative resistance** rate of isolates from all specimen types reported for 2016 **against penicillin**, using meningitis breakpoints, was at **6.1%** (n=427).

H. influenzae For 2016, **7.8% of isolates were resistant to ampicillin** (n= 461) and 5.8% were resistant to amoxicillin-clavulanic acid (n=431).



CAP in CHILDREN UP TO 5 YEARS

Etiology	Preferred Regimen	Comments
<p><i>S. pneumoniae</i> in 30%-50%</p> <p><i>Hib</i> in 10%-30%</p> <p><i>S. aureus</i></p> <p><i>K. pneumoniae</i></p> <p><i>NTHI</i></p>	<p><u>PCAP A or B</u></p> <p>If with complete Hib vaccination: Amoxicillin 80-90 mg/kg/d div q12h PO x 5d</p> <p>If with no Hib vaccination or incomplete or unknown vaccination history: Co-amoxiclav (80-90 mg/kg/d) OR Cefuroxime</p>	<p>Equal efficacy between oral amoxicillin and IV penicillin if feeding is tolerated.</p>

CAP in CHILDREN UP TO 5 YEARS

Etiology	Preferred Regimen	Comments
<p><i>S. pneumoniae</i> in 30%-50%</p> <p><i>Hib</i> in 10%-30%</p> <p><i>S. aureus</i></p> <p><i>K. pneumoniae</i></p> <p>NTHI</p>	<p><u>PCAP C:</u></p> <p>If with complete Hib vaccination:</p> <p>Penicillin OR Ampicillin</p> <p>If with no Hib vaccination:</p> <p>Cefuroxime OR Ceftriaxone OR Ampicillin-Sulbactam</p>	<p>Switch from IV to oral form 2-3 days after initiation of treatment in patients who are:</p> <ol style="list-style-type: none"> 1. Responding 2. Able to feed 3. Free from pulmonary/extrapulmonary complications

CAP in CHILDREN UP TO 5 YEARS

Etiology	Preferred Regimen	Comments
<p><i>S. pneumoniae</i> in 30%-50%</p> <p><i>Hib</i> in 10%-30%</p> <p><i>S. aureus</i></p> <p><i>K. pneumoniae</i></p> <p><i>NTHI</i></p>	<p><u>PCAP D:</u> Refer to Specialist; Admit to Critical Care Unit</p>	

OTITIS MEDIA

Etiology	Preferred Regimen	Comments
<p>Bacterial pathogens account for 85% of middle ear infections:</p> <ul style="list-style-type: none"><i>S. pneumoniae</i> in 49%<i>H. influenzae</i> in 29%<i>M. catarrhalis</i> in 28%. <p>Viruses cause up to 6% of middle ear infections.</p>	<p><u>First Line:</u> (No abx use the prior month) Amoxicillin 80-90mg/kg/d PO div q12h</p> <p>Treatment Duration:</p> <ul style="list-style-type: none"><2y: 10 d2-5y: 7 d>5y: 5-7d	<p>Prevention includes immunization against Hib, <i>Strep. pneumoniae</i></p>

OTITIS MEDIA

Etiology	Preferred Regimen	Comments
<p>Bacterial pathogens account for 85% of middle ear infections: <i>S. pneumoniae</i> in 49% <i>H. influenzae</i> in 29% <i>M. catarrhalis</i> in 28%.</p> <p>Viruses cause up to 6% of middle ear infections.</p>	<p><u>Second Line:</u> With anaphylaxis: Clarithromycin 15mg/kg/d PO q12h</p> <p>No anaphylaxis: Cefuroxime axetil 30mg/kg/d q12h DOT: <2y: 10 d; 2-5y: 7 d; >5y: 5-7d OR Ceftriaxone 50mg/kg/d IM/IV x 3d</p>	<p>For patients above 2 years old with no fever and ear pain with a negative or questionable exam, consider analgesic treatment without antimicrobials.</p> <p>There may be favorable results in mostly afebrile patients with waiting for 48 hours before deciding to use antibiotics.</p>

SINUSITIS

Etiology	Preferred Regimen	Comments
<p> <i>S. pneumonia</i> <i>H. influenzae</i> <i>M. catarrhalis</i> <i>S. aureus</i> Anaerobic bacteria Other Streptococcal sp. </p>	<p> <u>First Line:</u> Co-amoxiclav x 10-14d 1-3 mos.: 30mg/kg/d div q12h ≥3 mos.: 20-40mg/kg/d div q8h or 25-45mg/kg/d div q12h <i>For bid dosing, use the following formulations: 200/28.5mg or 400/57mg</i> </p>	<p> <u>Use Antibiotics If:</u> 1) with high fever and purulent nasal discharge or facial pain for > 3 days 2) still symptomatic after 10 days with no antibiotic 3) symptoms worsen after a typical viral illness that lasted 5 days and had initially improved. </p>

SINUSITIS

Etiology	Preferred Regimen	Comments
<p><i>S. pneumonia</i> <i>H. influenzae</i> <i>M. catarrhalis</i> <i>S. aureus</i> Anaerobic bacteria Other Streptococcal sp.</p>	<p><u>Second Line:</u> Co-amoxiclav ≥3 mos. AND <40 kg: 90 mg/kg/d q12h using 600/42.9mg/5 ml OR Cefuroxime 30mg/kg/d div q12h x min 10d</p> <p>For patients with severe penicillin allergy (pediatric): Type 1: Clarithromycin 15mg/kg/d div q12h Type 2: Cefuroxime 30mg/kg/d div q12h x min 10d</p>	

Case 4: Josie

*Is there a need to obtain
specimen for microbiologic testing
prior to treatment?*



LRTI Guidelines

Influenza

Empyema

Lung abscess

Pertussis

Ventilator-associated Pneumonia





Case 5: Jimmy

3 years old, male

loose bowel movement x 5 days

Other sx: vomiting, abdominal pain, high fever, anorexia

Relevant exposure: attends daycare where 2 children have been reported to have diarrhea

PE: lethargic, sunken eyes; distended abdomen, hyperactive bowel sounds, abdominal tenderness; rectal exam not done



Case 5: Jimmy

CBC: WBC 15,000; bands > segmenters

Electrolytes: ↓ Na, K, Ca

Stool exam: (+) fecal blood, >50 PMNs/HPF



Case 5: Jimmy

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 5: Jimmy

- A. Amoebiasis
- B. Dysentery
- C. Inflammatory Bowel Disease



ACUTE DIARRHEA AND GASTROENTERITIS

**Classification of dehydration status of children
2 months to 5 years of age (IMCI 2014):**

Severe dehydration

(when 2 of the following signs are present)

- Lethargic or unconscious / Sunken eyes
- Not able to drink or drinking poorly / Skin pinch goes back very slowly



ACUTE DIARRRHEA AND GASTROENTERITIS

**Classification of dehydration status of children
2 months to 5 years of age (IMCI 2014):**

Some dehydration

(when 2 of the following signs are present)

- Restless, irritable / Sunken eyes
- Drinks eagerly / Skin pinch goes back slowly



ACUTE DIARRRHEA AND GASTROENTERITIS

Etiology	Preferred Regimen	Comments
<p><u><12 months</u> Rotavirus ETEC <i>Cryptosporidium</i></p> <p><u>12-23 months</u> Rotavirus ETEC <i>Shigella</i></p>	<p>IMCI protocol for neonates up to 2 months:</p> <p><i>For dysentery:</i> Ciprofloxacin tab 30 mg/kg/d div 2 doses x 3d</p>	<p>IMMUNIZATION of infants starting at 6 weeks of age with either of 2 available live attenuated rotavirus vaccines is recommended to afford protection against severe rotavirus disease.</p>

ACUTE DIARRHEA AND GASTROENTERITIS

Etiology	Preferred Regimen	Comments
<p><u>24-59 months</u> Rotavirus <i>Shigella</i> <i>Vibrio cholera</i></p>	<p>IMCI protocol for child 2 months to 5 years:</p> <p><i>For cholera:</i> Erythromycin 250 mg tab qid x 3d OR Tetracycline</p> <p><i>For suspected dysentery:</i> Ciprofloxacin 30 mg/kg/d div 2 doses x 3d</p>	<p>ARSP 2016: Combined 2014-2016 data reveals emerging resistance of <i>Shigella</i> species against the fluoroquinolones with cumulative rate of resistance at 13.7% against ciprofloxacin (n=51).</p>

Case 5: Jimmy

*Is there a need to obtain
specimen for microbiologic testing
prior to treatment?*



ACUTE DIARRRHEA AND GASTROENTERITIS

Etiology	Preferred Regimen	Comments
<i>S. typhi</i>	<p><u>First Line:</u> Amoxicillin 75-100mg/kg/d q8h x 14d (Max: 500mg 2 caps q6h) OR Ampicillin 100-200mg/kg/d IV q6h x 14d (Max: 12g/24h) OR Chloramphenicol 50- 75mg/kg/d q6h x 14-21d (Max: 500mg 2 caps q6h) OR TMP-SMX 8mg/kg/d (TMP component) q12h x 14d</p>	

ACUTE DIARRRHEA AND GASTROENTERITIS

Etiology	Preferred Regimen	Comments
MDR <i>S. typhi</i>	<p><u>Second Line:</u> Cefixime 15-20mg/kg/d q12h x 7-10d (Max: 200mg 1 tab q12h) OR Azithromycin 20mg/kg/d q24h x 5-7d (Max: 500mg 1 tab q24h) OR Ciprofloxacin 30mg/kg/d q12h x 7-10d (Max: 500mg 1 tab q12h)</p>	<p>Second Line antibiotics reserved for suspected or proven MDR <i>S. typhi</i>:</p> <p>Failure to respond after 5-7 days tx with a first line antibiotic; Household contact with a documented case or during an epidemic of MDRTF; Clinical deterioration on tx</p>

ACUTE DIARRRHEA AND GASTROENTERITIS

Etiology	Preferred Regimen	Comments
<p>Nontyphoidal Salmonella (in the setting of severe diarrhea in infants less than 6 months, malnourished, immuno-compromised children)</p>	<p>Ceftriaxone 75-100 mg/kg/d IV q24h X 14d OR Azithromycin 6 mg/kg/d PO OD x 5d OR Ciprofloxacin 30 mg/kg/d IV in 2 div. doses x 10-14d</p>	<p>Increasing resistance of nontyphoidal salmonella to ciprofloxacin (n= 187) is noted with rate at 12.8% for 2016.</p>

GASTROINTESTINAL TRACT GUIDELINES

CAPD-Associated Peritonitis

Gallbladder Infection

Hepatitis A B C

Liver Abscess

Primary Spontaneous Bacterial Peritonitis

Secondary Peritonitis





Case 6: Meg

4 days old, female
fever by touch, poor feeding

Maternal & Birth History:

35 year old G1; unremarkable pre-natal and perinatal course; discharged within 24 hours from a lying-in clinic

PE: T-38.5 °C, CR-165, RR-61, weak cry, flat anterior fontanel, (-) jaundice, (-) alar flaring, supple neck, clear breath sounds, (-) murmur, (-) periumbilical erythema, soft abdomen, full pulses, CRT 2-3s,

(-) skin pustules



Case 6: Meg

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 6: Meg

- A. Dehydration Fever
- B. Neonatal Sepsis



SEPSIS

Etiology	Preferred Regimen	Comments
POTENTIALLY SEPTIC: asymptomatic, with documented maternal risk factors (UTI during last trimester, membranes ruptured >18h before delivery, fever > 38°C before delivery or during labor and/or purulent amniotic fluid)		
Gram-negative bacilli Group B Streptococcus <i>S. pneumoniae</i> <i>S. aureus</i>	Ampicillin PLUS Gentamicin OR Amikacin	Consider DC abx in infants who remain Asx and whose initial blood CS are negative after 72h

SEPSIS

Etiology	Preferred Regimen	Comments
NEONATAL SEPSIS: non-specific Sg and Sx or with focal signs of infection		
Gram-negative bacilli Group B Streptococcus <i>S. pneumoniae</i> <i>S. aureus</i>	First Line: Cefotaxime PLUS Gentamicin OR Amikacin Second Line: Ceftazidime PLUS Gentamicin OR Amikacin	Add Oxacillin or Vancomycin (MRSA) if with skin/soft tissue infections Precautions should be observed with Ceftriaxone



Case 7: Celia

- 5 weeks, female
- live preterm, 29 weeks by PA, 705 g, SGA, delivered by CS secondary to bleeding placenta previa, AS 8,9
- HMD s/p surfactant (1/13), resolved
- Nosocomial Pneumonia (1/20), resolved
- Clinical Nosocomial Sepsis, resolved (1/26)
- NEC Stage IIB, resolved
- PDA, s/p medical closure
- Candidemia (2/2), resolved
- *Klebsiella pneumoniae* MDRO Sepsis (2/15)



Case 7: Celia

What is your diagnosis?

What is the etiology?

What is your treatment?



Etiology	Preferred Regimen	Comments
HEALTHCARE-ASSOCIATED SEPSIS		
Gram-negative bacilli <i>S. aureus</i>	Ceftazidime OR Cefepime OR Piperacillin-Tazobactam OR Meropenem w/ or w/o Amikacin w/ or w/o Vancomycin	Choice of empiric antibiotic should be based on current antimicrobial susceptibility pattern within an institution

SEPSIS (MDRO): Microorganisms, predominantly bacteria that are resistant to one or more agents in 3 or more classes of antimicrobial categories.

MRSA VRE ESBL PRSP	Refer to Specialist	
-----------------------------	----------------------------	--

Case 7: Celia

*Is monotherapy acceptable or
is combination therapy required?*



Blood-borne Infections

Sepsis, without focus


Sepsis, intra-abdominal source

Sepsis, urinary source

Sepsis, severe and septic shock

TSS (Staphylococcal, Streptococcal)





Case 8: May

6 months, female

fever with associated cough over the last 4 days

feeding poorly for the last 2 days

brought for seizures

Immunization Hx: (+)BCG, (+) 1 Hepatitis B

Family Hx: BFC, 3 year old sibling (no shots)

PE: T- 39.5 °C, CR-150, RR-55, irritable; bulging anterior fontanel, (+) nuchal rigidity; diffuse coarse crackles; CRT 3s, (-) rash



Case 8: May

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 8: May

- A. Benign Febrile Convulsions
- B. Bacterial Meningitis
- C. Encephalitis



BACTERIAL MENINGITIS

Etiology	Preferred Regimen	Comments
<2 months <i>E. coli</i> <i>S. pneumoniae</i> <i>Klebsiella</i> <i>Enterobacter</i> <i>GBS</i>	Ampicillin OR Cefotaxime	Give antibiotics immediately after obtaining cultures Repeat LT in neonates to verify sterilization in gram-negative meningitis
>2 months-5 years <i>S. pneumoniae</i> <i>H. influenzae</i> * <i>N. meningitidis</i> *	Ceftriaxone OR Chloramphenicol	Add Dexamethasone for Hib meningitis; Give Rifampicin prophylaxis*
>5-18 years <i>S. pneumoniae</i> <i>N. meningitidis</i>	Ceftriaxone	

Case 8: May

CSF analysis:

Opening pressure: 250 mm H₂O

Turbid

Leucocytes: 2,000/mm³, PMNs predominate

Protein: 300 mg/dl

CSF to Serum Glucose Ratio: 20%

Gram Stain: (+) gram-negative coccobacilli

CSF Bactigen: requested

Treatment:

Ceftriaxone 100 mg/kg/24h



Case 8 : May

Is use of the drug for the condition supported by evidence?

Is the dose appropriate to the site and type of infection?



Case 9 : Lester

Lester is the 3 year old sibling of May
(probable Hib meningitis)

asymptomatic, normal PE



Case 9 : Lester

*Is there a need for prophylaxis
for exposed
close contacts of May?*



Rifampicin Prophylaxis

Patients <10 yrs. with confirmed Hib meningitis should receive Rifampicin prophylaxis to eradicate the carrier state.

Dose:

<3yrs: Rifampicin 10 mg/kg/day for 4 d

>3-10yrs: Rifampicin 20 mg/kg/day for 4 d

Max dose: 600 mg



CNS Guidelines

Brain Abscess

Encephalitis

Fungal Meningitis





Case 10: Betty

3 years, female

urinary frequency, dysuria, foul-smelling urine; no vomiting or any abnormal Sx

PE:

T-37.4 °C, (+) suprapubic pain on palpation



Case 10: Betty

Urinalysis:

(+) pyuria

(+) leucocyte esterase

(+) nitrite

Urine culture: awaiting result



Case 10: Betty

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 10: Betty

A. Acute Cystitis

B. Acute Pyelonephritis



UTI

Acute Uncomplicated UTI

Acute pyelonephritis: Condition that indicates renal parenchymal involvement where infants and children may present with fever with any or all of the following symptoms:

abdominal, back, or flank pain
malaise
nausea
vomiting
occasionally, diarrhea

Infants and children who have bacteriuria and fever $\geq 38^{\circ}\text{C}$ OR those presenting with fever $<38^{\circ}\text{C}$ with loin pain/tenderness and bacteriuria should be worked up for acute pyelonephritis.



UTI

Acute Uncomplicated UTI

Acute cystitis: condition that indicates urinary bladder involvement where infants and children may present with any or all of the following symptoms:

dysuria
urgency
frequency
suprapubic pain
incontinence
malodorous urine.

Patients usually have no systemic signs or symptoms.



UTI

Etiology	Preferred Regimen	Comments
<p><i>E. coli</i> <i>Klebsiella</i> <i>Enterobacter</i> <i>Enterococcus</i> GBS</p>	<p>Infants < 2 months: Cefotaxime</p> <p>PLUS</p> <p>Amikacin</p> <p>for 10-14 days</p>	<p>Early onset is usually due to maternal transmission.</p> <p>Adjust therapy based on culture.</p> <p>Use ceftriaxone if cefotaxime is not available and the neonate is not jaundiced.</p>

UTI

Etiology	Preferred Regimen	Comments
<p><i>E. coli</i> <i>Klebsiella</i> <i>Enterobacter</i> <i>Citrobacter</i></p>	<p>2 months to 18 years Oral options:</p> <p>Amoxicillin-clavulanate: <40 kg: 20-40 mg (amoxicillin)/kg/d q8h OR 25-45 mg/kg/d q12h using the 200 mg/5mL or 400 mg/5mL</p> <p>>40 kg: 500-875 mg q8h maximum dose: 2g/d OR</p> <p>Cefuroxime >3 mos - 12 yrs: 20 - 30 mg/kg/d PO q12h</p>	<p>Oral therapy is equally effective as IV therapy.</p>

UTI

Etiology	Preferred Regimen	Comments
<p><i>E. coli</i> <i>Klebsiella</i> <i>Enterobacter</i> <i>Citrobacter</i></p>	<p>Adolescents: Cefuroxime 250-500 mg PO q12h OR Nitrofurantoin (only for cystitis) 5-7 mg/kg/d q6h, maximum dose: 400 mg/d</p> <p>IV: Ampicillin-Sulbactam 100-200 mg/kg/d of ampicillin q6h IM or IV infusion over 10-15 min OR Cefuroxime 75-150 mg/kg/d q8h, max dose: 6 g/d. For those >40 kg, use adult dose.</p> <p>Duration of therapy (IV/PO): 7-14d</p>	<p>IV therapy is preferred for seriously ill children and for those who cannot take oral medications.</p>

Case 10: Betty

Started on oral Co-amoxiclav

Urine CS: *E. coli*, 100,000 col./ml urine

Sensitive:

Amoxicillin

Ampicillin

Amoxicillin-Clavulanic Acid

Amikacin

Cefuroxime

Ceftriaxone

Piperacillin-Tazobactam

Meropenem



Case 10: Betty

*Is my antibiotic of choice
the narrowest spectrum drug
to target the condition?*



UTI Guidelines


UTI recurrent

UTI catheter-related

UTI hospital acquired

Perinephric Abscess





Case 11: Sally & Liza

7 and 5 years old respectively, females

Recurrent purulent skin lesions over the last
8 months

1st episode: <2 cm abscess over L thigh; no antibiotics; hot packs applied with resolution

2nd episode: 6 cm abscess over the R axilla; I & D done; given Cotrimoxazole PO x 10 days c/o LHC

1st episode: 2 cm pimple-like lesion over the forehead with spontaneous rupture and resolution

2nd episode: 7 cm fluctuant mass over the R inguinal area, treated with Cloxacillin with no improvement



Case 11: Liza

PE: T-38.5 °C, 7 cm fluctuant mass,
R inguinal area with cellulitis



Case 11: Liza



Case 11: Sally & Liza

What is your diagnosis?

What is the etiology?

What is your treatment?



Case 11: Sally & Liza

- A. Abscess
- B. Lymphoma
- C. TB Adenitis



Skin and Soft Tissue Infections

Etiology	Preferred Regimen	Comments
<p>Etiology: <i>S. aureus</i>: Methicillin sensitive (MSSA), Methicillin resistant (MRSA)</p>	<p>Incision and drainage is the mainstay of therapy</p> <p>Cloxacillin 50-100mg/kg/d in 4 doses (Max: 2g/d) OR Cephalexin <u>Mild to moderate infections:</u> 25-50mg/kg/d in 3-4 doses <u>Severe infections:</u> 75-100mg/kg/d in 3-4 doses (Max: 4g/d)</p>	<p>Community-acquired MRSA is of increasing concern.</p>

Skin and Soft Tissue Infections

Etiology	Preferred Regimen	Comments
<p>Etiology: <i>S. aureus</i>: Methicillin sensitive (MSSA), Methicillin resistant (MRSA)</p>	<p>Oxacillin <u>Mild to moderate infections:</u> 100-150mg/kg/d IV/IM in 4 doses (Max: 4 g/d) <u>Severe infections:</u> 150- 200mg/kg/d IV/IM in 4-6 doses (Max: 12 g/d) OR</p> <p>Cefazolin <u>Mild to moderate infections:</u> 50mg/kg/d IV/IM in 3-4 doses (Max: 3g/d) <u>Severe infections:</u> 100-150mg IV/IM in 3-4 doses (Max: 6g/d)</p>	

Skin and Soft Tissue Infections

Etiology	Preferred Regimen	Comments
<p>Etiology: <i>S. aureus</i>: Methicillin sensitive (MSSA), Methicillin resistant (MRSA)</p>	<p>Second Line: Clindamycin 10-30mg/kg/d PO in 3-4 doses (Max: 1.8g/d) OR Cotrimoxazole 8-12mg/kg/d in 2 doses (TMP component) (Max: 320mg/d) OR Doxycycline 2-4mg/kg/d in 1-2 doses (Max: 200mg/d) OR Linezolid <u>Mild to moderate infections:</u> <12 yrs.: 30mg/kg/d in 3 doses ≥12 yrs.: 1200mg/d in 2 doses <u>Severe infections:</u> Same (Max: 1.2g/d) DOT: 7-10d</p>	

Skin and Soft Tissue Infections

Etiology	Preferred Regimen	Comments
<p>Etiology: <i>S. aureus</i>: Methicillin sensitive (MSSA), Methicillin resistant (MRSA)</p>	<p>Second Line: Clindamycin 25-40mg/kg/d IV in 3-4 doses (Max: 2.7g/d) OR Vancomycin 40-60 mg/kg/d IV in 4 doses (Max: 4 g/d) OR</p>	

Comments on SSTI

I & D: May treat patients with incision and drainage only and in outpatient setting if there is no diabetes or immunosuppression, and boil or abscess is **<5 cm** in diameter.

I & D PLUS Systemic therapy: may be effective in abscess **>5 cm** in diameter and in **multiple abscesses**.



Comments on SSTI

Antibiotic therapy is recommended for abscesses with the following conditions:

severe or extensive disease

(e.g., involving multiple sites of infection)

rapid progression in presence of cellulitis

presence of systemic inflammatory response syndrome (SIRS), such as temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$, tachypnea >24 breaths per minute, tachycardia >90 beats per minute, or white blood cell count $>12,000$ or <4000 cells/ μL



Comments on SSTI

Antibiotic therapy is recommended for abscesses with the following conditions:

associated comorbidities or immunosuppression;
extremes of age abscess

in areas difficult to drain (e.g., face, hand and genitalia)

lack of response to I&D alone



Comments on SSTI

An agent active against **MRSA** is recommended for any of the following:

Patients with carbuncles or abscesses who have failed initial antibiotic treatment against MSSA

Those with markedly impaired host defenses or

Those with SIRS and hypotension



Case 11: Sally & Liza

What is the minimum duration of therapy to treat the condition?



Case 11: Sally & Liza

*Are there other
adjuncts to treatment
apart from systemic antibiotics?*



Recurrent Staphylococcal Infections

Decolonization


Recurrent: 2 or more episodes in 1 year or other household members develop infection

Mupirocin ointment in anterior nares and under fingernails bid x 7d **PLUS** Chlorhexidine 4% shower daily x 7d

Bleach baths (tub of warm water with $\frac{1}{4}$ cup of 6% sodium hypochlorite (household bleach) for 15 minutes, is as effective as use of chlorhexidine shower body washes



ANTIBIOTIC



APOCALYPSE

National Antibiotic Guidelines

Are a core element of antimicrobial stewardship.

Provide guidance in the management of infectious diseases, in the selection of the most appropriate antimicrobial, to discourage the misuse of antimicrobials, and improve patient care.





MINDME

The Antimicrobial Creed

M microbiology guides therapy wherever possible

I indications should be evidence based

N narrowest spectrum required

D dosage appropriate to the site and type of infection

M minimise duration of therapy

E ensure monotherapy in most cases

Source: Therapeutic guidelines: antibiotic.
Version 14, 2010

National Antibiotic Guidelines

Are not intended to supersede a healthcare provider's clinical judgment.

Used by taking into account variation in a patient's clinical presentation (co-morbidities), patient preferences, and limitation in resources.





Rosalinda B. Soriano, M.D.



Estrella Paje-Villar, M.D.



Lulu C. Bravo, M.D.



Josefina C. Carlos, M.D.



Jaime A. Santos, M.D



Margaret Lu-Fong, M.D.



Celia C. Carlos, M.D.



May B. Montellano, M.D.



Lester A. Deniega, M.D.



Beatriz P. Quiambao, M.D.



Salvacion R. Gatchalian, M.D.



Ma. Liza M. Gonzales, M.D.

NAGCom

PIDSP Board Members

PIDSP Fellows/Diplomates:

Bone & Joint: [Grace Go/Edna Mallorca](#)

CNS/Dental: [Cecilia Lazarte](#)

CV: [Mercy Aragon/Ruth Sengson](#)

GI: [Celia Carlos](#)

Ocular: [Carmina delos Reyes](#)

RTI: [Carmina delos Reyes](#)

Sepsis: [Mary Ann Banez/Pia Torres](#)

SSTI: [Grace Go/Edna Mallorca](#)

STI: [Rosemarie Arciaga/Joanne de Jesus/Tricia Carino](#)



**Guidelines
do not
implement
themselves**

How is it used?

- <http://icamr.doh.gov.ph>
- **Antimicrobial Stewardship Toolkit**
 - **Antimicrobial Stewardship Program in Hospitals MOP**
 - **National Antibiotic Guidelines**



On behalf of NAGCOM

**WE WELCOME FEEDBACK
ON THE USE OF THE
NATIONAL ANTIBIOTIC GUIDELINES !**

E-mail address:

amr.secretariat@gmail.com



Acknowledgement

Dr. Mediadora Saniel



References

- All references are cited at the end of each guideline



URTI

- Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. (2012). Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. *Clinical Infectious Disease*, 54: e72-e112.
- Harris AM, Hicks LA, Qaseem A. (2016). Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. *Annals of Internal Medicine*, 164:425-34.
- Kimberlin, DW et al., ed. (2015). *Red Book: Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics.
- Bartlett JG, ed. (2015) *Johns Hopkins ABX Guide*. Baltimore, MD: Johns Hopkins University Hospital;



LRTI

- Antibiotic Guidelines 2015-2016. *Treatment Recommendations for Adult Inpatients*. Available at: http://www.hopkinsmedicine.org/amp/guidelines/antibiotic_guidelines.pdf
- Cherry JD, et al., eds. (2014). *Feigin and Cherry's Textbook of Pediatric Infectious Diseases*. 7th ed. Philadelphia, PA: Saunders.
- Kimberlin, DW et al., ed. (2015). *Red Book: Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics.
- Kliegman RM, et al., eds. (2016) *Nelson Textbook of Pediatrics*. 20th ed. Philadelphia, PA: Elsevier.
- Management of Adults with Hospital-acquired and Ventilator associated Pneumonia; 2016 Clinical Practice Guideline by the Infectious Diseases Society of American Thoracic Society. *CID* 2016:63



GIT

- Carlos C, Sanieel M. Etiology and epidemiology of diarrheas. Philipp J Microbiol Infect Dis 1990;19(2): 51-53.
- Cherry J, et al. Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th Edition. Philadelphia: Elsevier; 2015.
- Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. Philadelphia: Elsevier Inc., 2014.
- Integrated Management of Childhood Illness Chart Booklet. Geneva: World Health Organization; March 2014
- Jalan R, et al. Bacterial infections in cirrhosis; A position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60:1310-1324.



Blood-borne Infections

- Ahmed NM, et al. Fever in children with chemotherapy –induced neutropenia. Available at: <http://www.uptodate.com/contents/fever-in-children-with-chemotherapy-induced-neutropenia>.
- American Academy of Pediatrics, In: Kimberlin DW, Brady MT, et al.eds. Red Book 2015 Report of the Committee on Infectious Diseases,30th ed. Elk Grove Village.2015
- Antimicrobial Resistance Surveillance Program. Manila: Department of Health; 2015
- Bradley JS, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics.2009;123 (4): e609-e613.



CNS

- Baddour LM, Flynn PM, Fekete T. Infections of central nervous system shunts and other devices. UptoDate 2016. Accessed at: www.uptodate.com/contents/infections-of-central-nervous-system-shunts-and-other-devices.
- Bravo LC, Gatchalian SR, Gonzales ML, Maramba-Lazarte CC, Ong-Lim AT, Pagcatipunan MR, delos Reyes CA. Hand book of Pediatric Infectious Diseases 2012, 5th edition. Section of Infectious and Tropical Diseases, Manila 2012, pp 28-30.
- Centers for Disease Control and Prevention. 2013. Prevention and Control of Meningococcal Disease. Recommendations of the Immunization Practices (ACIP). MMWR 2013; 62 (No.2).
- Chaudhuri, A., Martin PM, Kennedy PGE, Seaton RA, Portegies P, Bojar M, Steiner I for the EFNS Task Force. 2008. EFNS guideline on the management of community meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Europ J Neurol 2008; 15: 649-659.



UTI

- Antimicrobial Resistance Surveillance Laboratory, Department of Health. Antimicrobial Resistance Surveillance Program 2015 Annual Report, Manila, Philippines 2016. Accessed at http://arsp.com.ph/wp-content/uploads/2016/06/2015-ARSP-annual-report-summary_1.pdf on September 7, 2016
- Bay AG, Anacleto F. Clinical and Laboratory Profile of Urinary Tract Infection Among Children at The Outpatient Clinic of A Tertiary Hospital. PIDSP Journal 2010;11(1):10-16.
- Bravo LC, Gatchalian SR, Gonzales ML, Maramba-Lazarte CC, Ong-Lim AT, Pagcatipunan MR, delos Reyes CA. Hand book of Pediatric Infectious Diseases 2012, 5th edition. Manila: Section of Infectious and Tropical Diseases; 2012.
- Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Pavia AT, Black DB, Freedman DO, Kim K, Schwartz BS editors. Sanford Guide to Antimicrobial Therapy 2016. VA: Antimicrobial Therapy, Inc.; 2016.



SSTI

- Baldwin G., Colbourne M. Puncture wounds. In Pediatrics in Review. 1999; 20 (1): 21-23.
- Bravo, Gatchalian, Gonzales, Maramba-Lazarte, Ong-Lim, Pagcatipunan, delos Reyes. Handbook of Pediatric Infectious Disease an Easy Guide 5th ed.
- Feigin R, Cherry J, et al. Textbook of Pediatric Infectious Diseases, 6th ed, 2009
- Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Black, Freedman DO, Pavia AT, Schwartz B. The Sanford Guide to Antimicrobial Therapy 2014, 44th edition.
- Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin- Resistant *Staphylococcus aureus* Infections in Adults and Children CID 2011: 52 (1 February)



***T*HANK YOU!**

***H*APPY ANNIVERSARY!**

